Eficacia y seguridad de un tratamiento oral a base de mucopolisacáridos, colágeno tipo i y vitamina C en pacientes con tendinopatías
- Andreu Arquer
- Miquel García
- José Antonio Laucirica
- Marta Rius
- Marian Blàvia
- Jaume Fontserè
- Carlos Hernández
- Jordi Boluda
- Tomislav Kranjcec
- Ana de la Torre Santos
- Gilberto Díaz
- Karin Freitag
- José M. Villalón
- Jaime Baselga
- Pedro Hernández
- José Gonzalez
- Guillermo Rodríguez
- Horacio Rodríguez
- Juan María Alarcón García
- Carlos T. Simorte
- Isaac Vicente
- Montserrat Cabañas Campos
- Pablo Ramírez
- Daniel Martínez Puig
ISSN: 1886-6581, 0213-3717
Année de publication: 2014
Volumen: 49
Número: 182
Pages: 31-36
Type: Article
D'autres publications dans: Apunts: Medicina de l'esport
Résumé
Introduction and objectives: The aim of this study was to evaluate the efficacy and safety a diet supplement containing mucopolysaccharides, collagen typei and vitamin C (Tendoactive ® ) on the clinical symptoms and tendon structure of patients with Achilles, patellar, or lateral epicondyle tendinopathy. Material and methods: Between September 2012 and February 2013, a total of 98 patients with tendinopathy were includedin the study (32 of Achilles tendon, 32 of patellar tendon, and 34 of lateral epicondyle tendon). The patients received a daily dose of Tendoactive ® containing435 mg of mucopolysaccharides, 75 mg of collagen type i and 60 mg of vitamin C (equivalent to 2 capsules per day) for 90 consecutive days, and were followed up monthly during the study period. Clinical assessments included pain intensity, which was assessed at rest and during activity using a visual analog scale (VAS), and also a specific functionalscale (VISA-A questionnaire for Achilles, VISA-P for patella, and PRTEE for the elbow).Tendon structure was analyzed using ultrasound, including measurements of cross-sectional hickness of the tendon, paratenon blurring, heteroechogenicity and hypoechogenicity levels, and neovascularization. Results: There was asignificant reduction in pain at rest and duing activity from the first follow- upvisit (day 30) until the end of the study (day90) for the three types of tendinopathy. The same pattern of response was observed with the functional scales. On day 90 the improvement from baseline was 38% for VISA-A, 6% for VISA-P, and 77% for PRTEE ( P <. 001). Simultaneous to the clinical improvement, there was a reduction of the tendon thickness (12%in Achilles, 10% in patellar tendon and 20% in lateral epicondyle tendon; P < .05). Conclusions: The overall results show that Tendoactive ® is a safe and effective treatment for improving the clinical symptoms,as well as structural evolutionof injured tendons, as demonstrated in Achilles, patellar and lateral elbow epicondyle tendinopathy